BioSpace News Archive

Biogen Inc. (Nasdaq: BIIB) and Samsung Bioepis Co., Ltd. today announced that BYOOVIZ™ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i has been launched in the United States.

Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced updated clinical data from its open-label Phase 1b/2 Study of Etigilimab and Nivolumab in subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE).

ProfoundBio announced the closing of a $70 million Series A+ financing round led by Sequoia China.

Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced the appointment of Amin Kamel, Ph.D., as Vice President, DMPK.

Apnimed, today announced that data from a proof-of-concept study exploring two potential oral therapeutic candidates for the treatment of patients with OSA, AD504 (atomoxetine + trazodone) and AD182, will be featured in an oral presentation at SLEEP 2022 in Charlotte, NC, on Monday, June 6.

Arsenal Biosciences, Inc., a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced that the company’s Chief Executive Officer, Ken Drazan, MD, will present in person at the 2022 Jefferies Healthcare Conference on Thursday, June 9 at 4:00 p.m. Eastern time.

Procaps Group S.A., a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced its preliminary financial results for the quarter ended March 31, 2022.

Featured speakers include Dr. John Krystal, Yale School of Medicine, and Dr. David Nutt, Imperial College London.

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced that Purnanand Sarma, PhD, President and CEO of Immunome, will present at the Jefferies Healthcare Conference on Thursday, June 9, at 2:30 p.m. ET.

Massive Bio, Inc. , a leader in precision medicine and artificial intelligence (AI) enabled patient centric clinical trial enrollment, raised $9 million.